KromaTiD launches new genome assay

By The Science Advisory Board staff writers

June 9, 2020 -- KromaTiD announced the launch of its new product, dGH In-Site, a single-cell, high-resolution, genome-wide DNA insert tracking assay.

The new product enables researchers to directly measure the degree of DNA integration at a target while also measuring off-target integrations. In combination with other targeted or de novo directional genomic hybridization (dGH) probes and paints, researchers can measure the distribution of inserts, profile structural variations, and measure edit site rearrangements.

KromaTiD's dGH In-Site provides robust characterization of heterogenous rearrangements and integration events with applications in gene therapy, genome editing, cellular engineering, undiagnosed diseases, and oncology, according to the company. The product offers high-specificity measurement of small DNA inserts to gene editing and pharmaceutical companies.

The product is the company's first standardized solution supporting the entire engineered cell market.

Spell-check gene editing corrects hearing loss in mice
Using a new genetic engineering technique called base editing, researchers restored genetic hearing loss in mice with a recessive point mutation. The...
Avectas, UCD partner on cell engineering
Avectas and the Simon Laboratory at UC Davis, California (UCD) will work together on cell-engineering technology.
Multiple recombination events may have led to SARS-CoV-2 in humans
A team of scientists evaluating how SARS-CoV-2 jumped to humans found that several genetic recombination events made it especially well-suited to infect...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter